
Ferring and Enteris to develop oral version of injectable peptide therapeutic
Executive Summary
US based Enteris BioPharma Inc. licensed its oral drug delivery technologies to Swiss-based Ferring Pharmaceuticals AS in order to develop an oral formulation of one of Ferring's peptide-based therapeutics.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice